Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ALKS 8700 in Healthy Adults
NCT02201849Phase 1Completed
- Sponsor
- Biogen
- Start
- Jul 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of diroximel fumarate in multiple sclerosis (MS) (3 arms), sponsored by Biogen. Primary endpoint: Incidence of adverse events up to 27 days. Started Jul 2014; status: completed.
02
Drugs
diroximel fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02201849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02201849.